Comparative Pharmacology
Head-to-head clinical analysis: BINOSTO versus FOSAMAX PLUS D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BINOSTO versus FOSAMAX PLUS D.
BINOSTO vs FOSAMAX PLUS D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
70 mg orally once weekly
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Category C
Category C
Bisphosphonate
Bisphosphonate